M2 Muscarinic Receptor Stimulation Induces Autophagy in Human Glioblastoma Cancer Stem Cells via mTOR Complex-1 Inhibition.

M2 muscarinic receptor apoptosis autophagy cancer stem cells glioblastoma mTORC1 orthosteric and dualsteric muscarinic agonism

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
20 Dec 2023
Historique:
received: 29 10 2023
revised: 12 12 2023
accepted: 16 12 2023
medline: 11 1 2024
pubmed: 11 1 2024
entrez: 11 1 2024
Statut: epublish

Résumé

Although autophagy is a pro-survival process of tumor cells, it can stimulate cell death in particular conditions and when differently regulated by specific signals. We previously demonstrated that the selective stimulation of the M2 muscarinic receptor subtype (mAChR) negatively controls cell proliferation and survival and causes oxidative stress and cytotoxic and genotoxic effects in both GBM cell lines and GBM stem cells (GSCs). In this work, we have evaluated whether autophagy was induced as a downstream mechanism of the observed cytotoxic processes induced by M2 mAChR activation by the orthosteric agonist APE or the dualsteric agonist N8-Iper (N8). To assess the activation of autophagy, we analyzed the expression of LC3B using Western blot analysis and in LC3B-EGFP transfected cell lines. Apoptosis was assessed by measuring the protein expression of Caspases 3 and 9. Our data indicate that activation of M2 mAChR by N8 promotes autophagy in both U251 and GB7 cell lines as suggested by the LC3B-II expression level and analysis of the transfected cells by fluorescence microscopy. Autophagy induction by M2 mAChRs is regulated by the decreased activity of the PI3K/AKT/mTORC1 pathway and upregulated by pAMPK expression. Downstream of autophagy activation, an increase in apoptosis was also observed in both cell lines after treatment with the two M2 agonists. N8 treatment causes autophagy via pAMPK upregulation, followed by apoptosis in both investigated cell lines. In contrast, the absence of autophagy in APE-treated GSC cells seems to indicate that cell death could be triggered by mechanisms alternative to those observed for N8.

Sections du résumé

BACKGROUND BACKGROUND
Although autophagy is a pro-survival process of tumor cells, it can stimulate cell death in particular conditions and when differently regulated by specific signals. We previously demonstrated that the selective stimulation of the M2 muscarinic receptor subtype (mAChR) negatively controls cell proliferation and survival and causes oxidative stress and cytotoxic and genotoxic effects in both GBM cell lines and GBM stem cells (GSCs). In this work, we have evaluated whether autophagy was induced as a downstream mechanism of the observed cytotoxic processes induced by M2 mAChR activation by the orthosteric agonist APE or the dualsteric agonist N8-Iper (N8).
METHODS METHODS
To assess the activation of autophagy, we analyzed the expression of LC3B using Western blot analysis and in LC3B-EGFP transfected cell lines. Apoptosis was assessed by measuring the protein expression of Caspases 3 and 9.
RESULTS RESULTS
Our data indicate that activation of M2 mAChR by N8 promotes autophagy in both U251 and GB7 cell lines as suggested by the LC3B-II expression level and analysis of the transfected cells by fluorescence microscopy. Autophagy induction by M2 mAChRs is regulated by the decreased activity of the PI3K/AKT/mTORC1 pathway and upregulated by pAMPK expression. Downstream of autophagy activation, an increase in apoptosis was also observed in both cell lines after treatment with the two M2 agonists.
CONCLUSIONS CONCLUSIONS
N8 treatment causes autophagy via pAMPK upregulation, followed by apoptosis in both investigated cell lines. In contrast, the absence of autophagy in APE-treated GSC cells seems to indicate that cell death could be triggered by mechanisms alternative to those observed for N8.

Identifiants

pubmed: 38201453
pii: cancers16010025
doi: 10.3390/cancers16010025
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Claudia Guerriero (C)

Department of Biology and Biotechnologies Charles Darwin, Sapienza University of Rome, 00185 Rome, Italy.

Marianna Manfredelli (M)

Department of Biology and Biotechnologies Charles Darwin, Sapienza University of Rome, 00185 Rome, Italy.

Carlo Matera (C)

Department of Pharmaceutical Sciences, University of Milan, 20133 Milan, Italy.

Angela Iuzzolino (A)

Department of Biology and Biotechnologies Charles Darwin, Sapienza University of Rome, 00185 Rome, Italy.
Institute of Molecular Biology and Pathology, National Research Council, 00185 Rome, Italy.

Luciano Conti (L)

Department of Cellular, Computational and Integrative Biology-CIBIO, University of Trento, 38123 Trento, Italy.

Clelia Dallanoce (C)

Department of Pharmaceutical Sciences, University of Milan, 20133 Milan, Italy.

Marco De Amici (M)

Department of Pharmaceutical Sciences, University of Milan, 20133 Milan, Italy.

Daniela Trisciuoglio (D)

Institute of Molecular Biology and Pathology, National Research Council, 00185 Rome, Italy.

Ada Maria Tata (AM)

Department of Biology and Biotechnologies Charles Darwin, Sapienza University of Rome, 00185 Rome, Italy.
Research Centre of Neurobiology Daniel Bovet, Sapienza University of Rome, 00185 Rome, Italy.
Consortium Interuniversity Biotechnologies (CIB), University of Ferrara, 44121 Ferrara, Italy.

Classifications MeSH